Pulmonary embolism cost-effectiveness of therapy: Difference between revisions
(Created page with "__NOTOC__ Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{Pulmonary embolism}} ==References== {{r...") |
m (Bot: Removing from Primary care) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Siren.gif|30px|link=Pulmonary embolism resident survival guide]]|| <br> || <br> | |||
| [[Pulmonary embolism resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{{Pulmonary embolism}} | |||
'''Editor(s)-In-Chief:''' {{ATI}}, [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]; {{AE}} {{Rim}} | |||
{{ | ==Overview== | ||
When indicated, early discharge and outpatient treatment for pulmonary embolism is more cost effective than inpatient treatment.<ref name="pmid16162764">{{cite journal| author=Aujesky D, Smith KJ, Cornuz J, Roberts MS| title=Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. | journal=Chest | year= 2005 | volume= 128 | issue= 3 | pages= 1601-10 | pmid=16162764 | doi=10.1378/chest.128.3.1601 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16162764 }} </ref> The inpatient treatment with [[low molecular weight heparin]] has been reported to be more cost effective than that with [[unfractionated heparin]].<ref name="pmid16162764">{{cite journal| author=Aujesky D, Smith KJ, Cornuz J, Roberts MS| title=Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. | journal=Chest | year= 2005 | volume= 128 | issue= 3 | pages= 1601-10 | pmid=16162764 | doi=10.1378/chest.128.3.1601 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16162764 }} </ref> | |||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
| Line 12: | Line 22: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | [[Category:Intensive care medicine]] | ||
Latest revision as of 23:53, 29 July 2020
 |
Resident Survival Guide |
|
Pulmonary Embolism Microchapters |
|
Diagnosis |
|---|
|
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores |
|
Treatment |
|
Follow-Up |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Pulmonary embolism cost-effectiveness of therapy On the Web |
|
Pulmonary embolism cost-effectiveness of therapy in the news |
|
Directions to Hospitals Treating Pulmonary embolism cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pulmonary embolism cost-effectiveness of therapy |
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
When indicated, early discharge and outpatient treatment for pulmonary embolism is more cost effective than inpatient treatment.[1] The inpatient treatment with low molecular weight heparin has been reported to be more cost effective than that with unfractionated heparin.[1]
References
- ↑ 1.0 1.1 Aujesky D, Smith KJ, Cornuz J, Roberts MS (2005). "Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism". Chest. 128 (3): 1601–10. doi:10.1378/chest.128.3.1601. PMID 16162764.